



HAL
open science

Reply to: Letter to the Editor by Martínez-Fernández

Yvan Vachez, Carole Carcenac, Robin Magnard, Lydia Kerkerian-le Goff,
Pascal Salin, Marc Savasta, Sebastien Carnicella, Sabrina Boulet

► To cite this version:

Yvan Vachez, Carole Carcenac, Robin Magnard, Lydia Kerkerian-le Goff, Pascal Salin, et al.. Reply to: Letter to the Editor by Martínez-Fernández. *Movement Disorders*, 2020, 35 (6), pp.1084-1085. 10.1002/mds.28082 . hal-03009190

HAL Id: hal-03009190

<https://hal.science/hal-03009190v1>

Submitted on 17 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Reply to the Letter to the editor regarding “Subthalamic nucleus stimulation impairs motivation: implication for apathy in Parkinson’s Disease”

Authors :

Yvan Vachez, PhD^{1,2}, Carole Carcenac, PhD^{1,2}, Robin Magnard, PhD^{1,2}, Lydia Kerkerian -Le Goff, PhD³, Pascal Salin, PhD³, Marc Savasta, PhD^{1,2}, Sebastien Carnicella, PhD^{1,2} and Sabrina Boulet, PhD^{1,2}

Affiliations :

¹Inserm, U1216, F- 38000 Grenoble, France.

²Univ. Grenoble Alpes, Grenoble Institut des Neurosciences, GIN, F-38000 Grenoble, France.

³Aix Marseille Univ, CNRS, IBDM, Marseille, France.

Corresponding author:

Dr Sabrina Boulet and Dr Marc Savasta

INSERM U1216, Grenoble Institute of Neuroscience, Group “Pathophysiology of Motivation”,
Grenoble Université - Site Santé La Tronche - BP 170, 38042 Grenoble, France.

Phone: 33 4 56 52 06 70;

Email addresses: sabrina.boulet@univ-grenoble-alpes.fr ; marc.savasta@inserm.fr

Word count: 434

We thank Dr Raul Martínez-Fernández for his comment concerning our publication¹ and for the opportunity to discuss our data in more detail, especially with an expert on apathy in Parkinson's Disease (PD).

Whether apathy associated with subthalamic nucleus deep brain stimulation (STN-DBS) is a consequence of the reduction of dopaminergic replacement therapy (DRT), as considered in the prevailing clinical opinion, or a direct psychiatric side effect of the stimulation itself, remains an unsolved issue. Exploring this question with preclinical approaches allows examining separately potentially interacting factors. However, we agree it also presents limitations, as pointed out by Dr Martínez-Fernández, and already acknowledged in the discussion of the present publication⁴. Although, in our work, the effects of STN-DBS were consistent in all the animals carefully and rigorously included based on correct placement of the electrode, given the size of the STN, spreading outside the targeted STN region, such as to zona incerta, cannot be excluded, especially when applying a monopolar stimulation. Of note however, monopolar stimulation was consciously chosen in our study to model at best DBS as in the clinic¹.

In this context, our work showed in rats that chronic STN-DBS diminishes reward seeking and basal activity in both control animals, without any dopamine degeneration, and in a model of PD-neuropsychiatric manifestations, in the absence of any prior dopamine medication¹. It thus provides evidence that STN-DBS by itself could promote loss of motivation reminiscent of apathy in PD, without excluding interaction with the neurodegeneration profile and medication history in patients. Even though the pathophysiological explanations afforded by our study remain limited, the reversion of the STN-DBS-induced motivational deficit by pramipexole, a D₂R/D₃R agonist that alleviates apathy in PD patients, argues for a mechanism involving these receptors, in line with our previous observation of decreased D₂R/D₃R under acute STN-DBS², which we will try to dissect in the future.

In addition, the bivalent role of STN, in positive and negative reward and emotional processes³, as well as its complex implication at the intersection of the motor, associative and limbic interconnected basal ganglia loops have been extensively investigated and can largely

account for paradoxical effects of DBS ranging from apathy to euphoria, depending on the parameters of stimulation as well as localization. For instance, location within or close to the border of the so called “limbic” ventral STN has been described either to improve⁴ or worsen apathy⁵ in PD patients, revealing not only a complex action of DBS in animal models but also in the clinic. Also, regarding stimulation setting, whether the spectrum cursor for motor function and for behavior is the same remains to be established.

To conclude, while acknowledging its limitations, our work brought new relevant elements, perhaps counterintuitive, but not at odds with our current understanding of the STN, fueling constructively the debate on the question “can STN-DBS induce apathy?”.

1. Vachez Y, Carcenac C, Magnard R, et al. Subthalamic nucleus stimulation impairs motivation: Implication for apathy in Parkinson's disease. *Movement disorders : official journal of the Movement Disorder Society* 2020.
2. Carcenac C, Favier M, Vachez Y, et al. Subthalamic deep brain stimulation differently alters striatal dopaminergic receptor levels in rats. *Movement disorders : official journal of the Movement Disorder Society* 2015;30(13):1739-1749.
3. Breysse E, Pelloux Y, Baunez C. The Good and Bad Differentially Encoded within the Subthalamic Nucleus in Rats(1,2,3). *eNeuro* 2015;2(5).
4. Petry-Schmelzer JN, Krause M, Dembek TA, et al. Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. *Brain : a journal of neurology* 2019;142(11):3592-3604.
5. Zoon TJ, de Bie RM, Schuurman PR, van den Munckhof P, Denys D, Fiege M. Resolution of apathy after dorsal instead of ventral subthalamic deep brain stimulation for Parkinson's disease. *Journal of neurology* 2019.